Introduction
============

Since Parkinson's disease (PD) has no cure current therapeutics target motor systems to either increase dopamine production or adjust the impact of other neurotransmitters, but these treatments are likely to eventually fail. Human pluripotent stem cell (hPSC) derived midbrain dopaminergic (mDA) neurons have captured the imagination of public and scientists alike as a source of cells for disease arresting cell replacement therapies for PD ([@B19]; [@B25]). However, our contention is that hPSC-derived mDA neurons, with genetic modifications designed to enhance their utility, could promote the next generation of *in vitro* pathophysiological modeling and drug discovery studies. Recent modeling studies have used reprogramming technology to generate hPSCs derived mDA neurons from patients with PD with an aim to specifically investigate the role of single gene mutations on neuron function and survival ([@B7]; [@B37]; [@B44]). More generic model systems often employ neurotoxins such as 6-hydroxydopamine or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to induce degeneration of the A9 dopaminergic neurons. In these models of PD the neurotoxin-induced degeneration of the A9 neurons appears to be dependent upon the activity of tumor necrosis factor alpha (TNF) which is elevated in the striatal tissue of mice and rats following the injection of MPTP or 6-hydroxydopamine ([@B34]; [@B50]). Critically, suppression of TNF reduces neurodegeneration in these model systems ([@B30], [@B31]; [@B51]). While the underlying causes of PD are the subject of much speculation, this evidence of a role for TNF in the degenerative process is consistent with oxidative stress contributing to PD. In this system a transient initiating factor (an infection or neurotoxin) triggers a chronic cycle of neuroinflammation which promotes clustering of activated microglia in the basal ganglia and striatum of patients with PD, promoting degeneration ([@B8]). Microglia are important regulators of neuron function. In addition to phagocytic activity, they are capable of releasing trophic factors, such as brain cell line-derived neurotrophic factor (BDNF; [@B35]), as well as a number of pro-inflammatory mediators, including chemokines, reactive oxygen and nitrogen species, prostaglandin E~2~ and TNF. Both TNF and TNF receptor (R1) are elevated in the cerebrospinal fluid and nigral tissue of patients with PD ([@B32], [@B33]). Also, patients with gain of function mutations in the TNF promoter region show an increased risk of early onset PD ([@B38]; [@B2]). In spite of this evidence there is no direct empirical evidence linking TNF with the death of human A9 neurons.

One of the major problems underlying mechanistic investigations of the role of TNF in human neurodegeneration has been the lack of an adequate *in vitro* system to facilitate these investigations. Human stem cell cultures and methods to push neurons toward a dopaminergic neuron fate have improved considerably over the last 6--7 years. However, a major problem with hPSC-derived mDA neural cultures is that current differentiation protocols, even the few that can be replicated in other laboratories (such as [@B23]), still generate a heterogeneous mix of cells in culture that make it difficult to observe or quantify effects. To address this shortcoming we have created a human homologous recombinant stem cell line that expresses a fluorescent reporter gene (eGFP) under the control of a midbrain specific DA neural endogenous promoter (PITX3) to enable the identification of PITX3-eGFP positive (*PITX3^eGFP/w^*) mDA neurons within the culture. We now report that *PITX3^eGFP/w^* neurons are evident from day 20 of differentiation although they take approximately 70 days to reach functional maturity; defined by low levels of intracellular chloride and resting calcium. These neurons are responsive to a number of pharmacological stimuli, but the pharmacological responsiveness of these neurons changes as they mature: early in the course of maturation individual neurons are likely to respond to any of the neurotransmitters, ATP, glutamate, noradrenaline, and acetylcholine with elevations of intracellular calcium, but as these neurons mature they are likely to become responsive to all four ligands. At maturity the *PITX3^eGFP/w^* neurons show a transcript profile indicative of mDA neurons (including PITX3, tyrosine hydroxylase, and TUJ1). We assessed the ability of a neurotoxin (MPP^+^) as well as neuroinflammatory mediators TNF and prostaglandin E~2~ to promote neuron death and neurite retraction of these cultures. MPP^+^ is a powerful toxin in these cells and TNF, but not PGE2, causes some death as well as neurite retraction. In summary, we show that *PITX3^eGFP/w^* neurons are ideal tools for the investigation of mDA neuron development, the pharmacological characterization of receptor populations, as well as *in vitro* neurodegeneration studies.

Materials and Methods {#s1}
=====================

hPSC Culture and PITX3^eGFP/w^ Cell Line Generation Using Zinc-Finger Nucleases
-------------------------------------------------------------------------------

The initial hPSC line (H9) was cultured on MEFs (mitomycin C treated mouse embryonic fibroblasts, 4 × 10^5^ cells cm^-2^) in hPSC media: Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12, 1:1; Invitrogen, Australia), 20% Knock-Out Serum (Invitrogen, Australia), 1% NEAA, 2 mM GlutaMAX^TM^-I, penicillin 25 U mL^-1^, streptomycin 25 μg mL^-1^, 0.1 mM β-mercaptoethanol and 6 ng mL^-1^ FGF-2. Media was changed daily. hPSC cultures were manually groomed to remove differentiated colonies. Fragments (∼0.5 mm^2^ diameter) were manually passaged every 5--7 days onto freshly prepared MEFs.

To create the *PITX3* homologous recombinant cell line, pluripotent H9 human embryonic stem cells (hESCs) were harvested using Accutase and plated on 0.1% v/v gelatin coated dishes in hPSC media containing Rho-associated protein kinase inhibitor (10 μM, Y-27632; Cellagen Technology, USA). Following 30 min incubation the non-adherent hPSCs were collected, centrifuged (200 ×*g*, 5 min), resuspended (7.5 × 10^6^ cells) in 800 μL of 0.22 μm filtered ice cold PBS and transferred to a 0.4 cm electroporation cuvette (Bio-Rad, Australia) together with 10 μg of custom designed ZFN pairs (Sigma-Aldrich, Australia) and 40 μg of a previously described EGFP targeting vector ([@B14]) obtained from Addgene (USA). Electroporation was conducted at 250 V, 500 μF (GenePulser XCell instrument; Bio-Rad, Australia) and the electroporated cells plated on MEFs in hPSC medium containing a ROCK inhibitor for the first 24 h. Individual colonies were incubated with puromycin (0.5 μg mL^-1^, Invitrogen, Australia) for 10--14 days after electroporation, at which time puromycin resistant colonies were manually picked and expanded for screening.

For screening correctly targeted colonies, genomic DNA was prepared as previously described ([@B36]). Pooled colonies were initially screened by PCR using the Expand Long Template PCR System (Roche, Australia). PCR positive clones were then further screened by Southern blotting. Digested genomic DNA was electrophoresed, transferred to Hybond-N^+^ membranes (GE Healthcare, Australia) and hybridized with external probes complementary to sequences upstream of the 5′ homology arm of the vector and downstream of the 3′ homology arm, as well as an internal puromycin probe. Probes were labeled with α-32P-dATP (Perkin Elmer, Australia) using a DECAprimeTM II kit (Ambion, Texas) and hybridized in ULTRAhybTM hybridization buffer (Ambion, Texas). The signal was detected using Kodak BioMax MS film in a BioMax Cassette with BioMax TranScreen HE (Sigma-Aldrich, Australia).

PITX3^eGFP/w^ Neuron Differentiation and Visualization
------------------------------------------------------

For differentiation, *PITX3^eGFP/w^* hPSC fragments were transferred to Geltrex (Stem Cell Technologies, Australia) coated six well-plates in mTeSR-1 (Stem Cell Technologies, Australia) media. After 3 days, or when wells were 50--60% confluent, cells were washed thrice in 1X PBS and grown thereafter in a 1:1 mixture of modified Neurobasal and modified DMEM/F12 medium (N2B27 media; [@B3]). Additives to this medium were based on the conditions found in [@B23] and included LDN 193189 (LDN, 100 nM; Axon Medchem, Netherlands) from days 0 to 10, SB 431542 (SB, 10 μM; Sigma-Aldrich, Australia) from days 0 to 5, recombinant mouse Sonic Hedgehog C25II (SHH, 100 ng mL^-1^; R&D Systems, USA), recombinant mouse fibroblast growth factor-8b carrier-free (FGF8, 100 ng mL^-1^; R&D Systems, USA), and purmorphamine (PUR, 2 μM; Santa Cruz Biotechnology, USA) from days 1 to 7, CHIR 99021 (CHIR, 3 μM; Tocris Bioscience, USA) from days 3 to 13, and recombinant human glial cell line-derived neurotrophic factor (GDNF (20 ng mL^-1^; R&D Systems, USA), recombinant human BDNF (20 ng mL^-1^; R&D Systems, USA), ascorbic acid (AA, 200 nM; Sigma-Aldrich, USA), DAPT (10 nM; Sigma-Aldrich, USA), N^6^, 2′-*O*-dibutyryladenosine-3′, 5′-cyclic monophosphate (db-cAMP, 0.5 mM; Biolog Life Science Institute, Germany), and recombinant human TGF-β 3 (TGF-β, 1 ng mL^-1^; R&D Systems, USA) from day 10 onward. Cells could be grown on the Geltrex plates until at least day 80 of differentiation (with every-other-day media changes); alternatively after day 20 fragments of cells (roughly 2--3 mm in diameter) could be gently cut away from growing colonies using the tip of a P200 pipette and transferred to laminin (1 mg mL^-1^) coated plates. Colonies were grown in supplemented N2B27 (as described above) until experimentation. eGFP fluorescence during differentiation was confirmed using flow cytometry (below), and visualized with a Nikon A1R confocal microscope (Nikon Instruments, USA).

Flow Cytometry and Sorting
--------------------------

To characterize differentiating cultures, starting at day 0 of differentiation and continuing at 3 days intervals until day 21, cells were dissociated using Accutase (Sigma-Aldrich, Australia), and resuspended in 1X HBSS (Invitrogen, Australia) containing 10% FCS, and 2 mM glucose at 37^∘^C for cytometric analysis of eGFP fluorescence. Cell suspensions were strained (40 μm; BD Biosciences, Australia) to minimize clumps, and incubated with 5 nM SYTOX Blue (Invitrogen, Australia) to stain for dead cells. Analysis was performed on a FACS Canto II flow cytometer (BD Biosciences, Australia). eGFP fluorescence exclusion gating was employed to ensure that \>99% of the wild type control population (also subjected to the same staining) were eGFP-negative. The key to neuron survival using this approach is to have as low a pressure, and as wide a nozzle as possible.

Cells were also FACS sorted for mRNA extraction and subsequent qPCR. On days 0, 20, 40, 60, and 80, cells were dissociated using accutase, strained, and resuspended as above. FACS was performed using a MoFlo Astrios sorter (Beckman Coulter Inc., USA) and cells divided into eGFP positive and eGFP negative fractions. The positive and negative fractions from the aggregates of three independently differentiating wells (to ensure sufficient cells for each sort) were centrifuged at 200 ×*g* for 5 min and the supernatant removed prior to RNA extraction.

RNA Extraction and Quantitative-PCR
-----------------------------------

Total RNA was extracted from 10^6^ cells using the RNEasy Minikit according to manufacturer's instructions (Qiagen, Australia). Samples were analyzed for RNA content using the Nanodrop ND-1000 (Thermo Scientific, USA) spectrophotometer. Three technical replicate qPCR reactions were performed on samples aggregated from three independently differentiating wells using the iScript One-Step RT-PCR Kit with SYBR-Green according to the manufacturer's specifications (Bio-Rad, Australia). qPCR reactions and primer sequences are described in **Table [1](#T1){ref-type="table"}**. Relative quantification of gene expression during differentiation was obtained using the 2^-ΔΔCt^ method ([@B26]) by comparing Ct values of target genes to mean Ct values of two housekeeping genes, β-actin and GAPDH.

###### 

Quantitative polymerase chain reactions (qPCRs) were performed in the C1000 Thermal Cycler coupled to a CFX96 Real Time System (Bio-Rad, Australia).

  Gene       Fwd/Rev   Sequence 5′ to 3′                Melt ^∘^C
  ---------- --------- -------------------------------- -----------
  *TH*       Fwd       CGG GCT TCT CGG ACC AGG TGT A    73.2
             Rev       CTC CTC GGC GGT GTA CTC CAC A    72.6
  *AADC*     Fwd       CTC GGA CCA AAG TGA TCC AT       63.9
             Rev       GTC TCT CTC CAG GGC TTC CT       63.8
  *NURR1*    Fwd       TTC TCC TTT AAG CAA TCG CCC      66.1
             Rev       AAG CCT TTG CAG CCC TCA CAG      69.8
  *PITX3*    Fwd       GCC AAC CTT AGT CCG TG           59.2
             Rev       GCA AGC CAG TCA AAA TG           57.8
  *DAT*      Fwd       AGC AGA ACG GAG TGC AGC T        65.4
             Rev       GTA TGC TCT GAT GCC GTC T        60.5
  *FOXG1*    Fwd       TGG CCC ATG TCG CCC TTC CT       75.1
             Rev       GCC GAC GTG GTG CCG TTG TA       73.5
  *NKX2.1*   Fwd       AGG GCG GGG CAC AGA TTG GA       75.1
             Rev       GCT GGC AGA GTG TGC CCA GA       71.4
  *PAX5*     Fwd       CCC CAT TGT GAC AGG CCG TGA C    74.8
             Rev       TCA GCG TCG GTG CTG AGT AGC T    70.5
  *EN1*      Fwd       TCT CGC TGT CTC TCC CTC TC       63.9
             Rev       CGT GGC TTA CTC CCC ATT TA       63.6
  *WNT1*     Fwd       GAG CCA CGA GTT TGG ATG TT       64.0
             Rev       TGC AGG GAG AAA GGA GAG AA       64.0
  *GIRK2*    Fwd       GCT ACC GGG TCA TCA CAG AT       63.9
             Rev       ACT GCA TGG GTG GAA AAG AC       63.9
  *LMX1A*    Fwd       CGC ATC GTT TCT TCT CCT CT       63.4
             Rev       CAG ACA GAC TTG GGG CTC AC       65.0
  *FOXA2*    Fwd       GGG GTA GTG CAT CAC CTG TT       63.8
             Rev       CCG TTC TCC ATC AAC AAC CT       63.9
  *SHH*      Fwd       CCA ATT ACA ACC CCG ACA TC       63.9
             Rev       AGT TTC ACT CCT GGC CAC TG       64.3
  *CORIN*    Fwd       CAT ATC TCC ATC GCC TCA GTT G    65.6
             Rev       GGC AGG AGT CCA TGA CTG T        62.9
  *HOXA2*    Fwd       CGT CGC TCG CTG AGT GCC TG       74.1
             Rev       TGT CGA GTG TGA AAG CGT CGA GG   72.7
  *ACTB*     Fwd       CCT TGC ACA TGC CGG AG           66.9
             Rev       GCA CAG AGC CTC GCC TT           64.6
  *GAPDH*    Fwd       TTG AGG TCA ATG AAG GGG TC       63.9
             Rev       GAA GGT GAA GGT CGG AGT CA       64.6
  *OCT4*     Fwd       TCT CCA GGT TGC CTC TCA CT       64.1
             Rev       GTG GAG GAA GCT GAC AAC AA       62.9
  *MAP2*     Fwd       CCG TGT GGA CCA TGG GGC TG       75.3
             Rev       GTC GTC GGG GTG ATG CCA CG       75.4
  *SYP*      Fwd       ACC TCG GGA CTC AAC ACC TCG G    72.6
             Rev       GAA CCA CAG GTT GCC GAC CCA G    73.8
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∘

C), reverse transcriptase inactivation (5 min at 95

∘

C), PCR cycling (10 s at 95
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C; up to 43 cycles), and melt curve analysis (1 min at 95
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∘

C, and 10 s each at steps of 0.5
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C between and 55--95

∘

C). Primers used in gene expression assay.

Immunocytochemistry
-------------------

Immunocytochemistry was carried out as previously described ([@B18]). Briefly, cells were washed free of PBS/sodium azide (3 × 5 min in PBS) and permeabilized with 0.1% Triton X-100 (Sigma-Aldrich, Australia) in PBS for 30 min at room temperature. Cells were then blocked with 1% normal donkey serum in PBS for 30 min and incubated overnight in 0.1% Triton X-100 in PBS with the primary antibodies, anti-tyrosine hydroxylase (TH; rabbit IgG, 1:200; Millipore, Australia), anti-βIII tubulin (mouse IgG, 1:1000; Covance, Australia), anti-FOXA2 (mouse IgG, 1:1000; DHSB, USA), anti-GABA (rabbit IgG, 1:200; Sigma-Aldrich, Australia), anti-GIRK2 (rabbit IgG, 1:200; Alomone labs, Israel), and anti-LMX1A (rabbit IgG, 1:200; Sigma-Aldrich, Australia). Cells were then incubated with the secondary antibodies donkey anti-mouse Alexa Fluor 488 and donkey anti-rabbit Alexa Fluor 594 (both Molecular Probes, USA) at 1:1000 for 2 h at room temperature. Cells were visualized using a Nikon TE2000U microscope coupled to a SPOT RT camera (for post live-cell imaging immunocytochemistry) or a Nikon A1R confocal microscope (for other immunocytochemistry; Nikon, Japan). Fields of view corresponding with those used for Ca^2+^ and Cl^-^ ion imaging studies were identified by aligning initial images with those taken after immunolabeling. TH immunoreactive and eGFP positive (TH^+^eGFP^+^) neurons were identified and regions defined so that \[Ca^2+^\]~i~ and \[Cl^-^\]~i~ responses in those neurons could be determined after replaying the initial live cell experiments.

Live Cell Calcium and Chloride Ion Imaging
------------------------------------------

Calcium and chloride ion imaging was performed on days 20, 40, 60, and 80 as described previously ([@B13]; [@B54]). For calcium imaging; neurons were incubated in HEPES buffered salt solution (consisting of NaCl, 145 mM; KCl, 5 mM; MgSO~4~, 1 mM; HEPES, 10 mM; CaCl~2~, 2 mM; glucose, 10 mM, containing 0.1% bovine serum albumin, at pH 7.4) in the presence of 5 μM FURA-2AM (ICN Biochemicals) for 40 min. Cells were then allowed to hydrolyze the acetoxymethyl ester for 40--60 min (37^∘^) prior to viewing with a Nikon TE2000U microscope coupled to a SPOT RT camera (for post live-cell imaging immunocytochemistry) or a Nikon A1R confocal microscope. Cell temperature was maintained at near 37^∘^C with a heated stage. A DG4 (Sutter, USA) was used to illuminate cells with light at 340 and 380 nm. Cell fluorescent emission at 510 nm was recorded every 1--2 s. Background emission was subtracted from each image, and 340/380 ratios of the resultant intensity emission values at each time point were obtained.

For intracellular calcium quantitation, the calcium concentration was calculated using the equation ([@B10]):
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Where β is the emission ratio of R~min~/R~max~ at 380 nm. The dissociation constant (*K~D~*) value of 285 nM was taken from ([@B9]). The R~min~ value was obtained in the absence of Ca^2+^ and in the presence of both 4-Br-A232187 (20 μM) and EGTA (10 mM). The R~max~ value was obtained in the presence of both 4-Br-A232187 (20 μM) and Ca^2+^ (10 mM).

For non-quantitative calcium imaging neurons were loaded with Fluo4AM (10 μM 30 min) as described previously ([@B17]). Briefly, following a 30 min equilibration period minute equilibration period and 10 min of baseline imaging either of the agonists adenosine triphosphate (ATP, 300 μM), noradrenaline (NA, 30 μM), acetylcholine (ACh, 30 μM), [L]{.smallcaps}-glutamate (Glut, 30 μM), γ-aminobutyric acid (GABA, 30 μM; all Sigma-Aldrich, Australia), We have previously shown these concentrations to be effective in elevating \[Ca^2+^\]~i~ in mDA neurons ([@B24]; [@B42]; [@B17]) Following peak response or after 5 min, wells were washed three times with PBS and preparations allowed at least 5 min to recover before the addition of the next agonist. This was repeated until all five agonists had been added. After the final agonist addition wells were washed and KCl (30 mM) added.

For voltage operated calcium channel inhibitor studies cells were loaded with Fluo-4AM (as described above). Following a 10 min equilibration period KCl (30 mM) was added to culture plates and changes in fluorescence intensity recorded over 30 s. Preparations were then washed and nifedipine (10 μM) was added, 5 min later KCl was added again and changes in fluorescence intensity recorded. Preparations were washed and nifedipine re-added, along with ω-conotoxin (0.4 μM) and responses to KCl measured again. This process was repeated with the addition of mibefradil (10 μM). Control responses to KCl (30 mM, x4) were measured in the presence voltage operated calcium channel inhibitor vehicle.

For chloride ion imaging we used the method previously described ([@B54]). Briefly, we incubated neurons with the Chloride-sensitive fluorophore dihydro-MEQ (10 μM; [@B15]) in normal HEPES buffer, measuring fluorescence intensity following excitation at 340/26 nm; emission was recorded at 510/84 nm. Resting state fluorescence and fluorescence following the addition of GABA (30 μM) were recorded. We changed to a Cl^-^ free buffer (normal HEPES with gluconate ions replacing Cl^-^) containing nigericin (10 μM), tributyltin (10 μM), and valinomycin (5 μM) to measure minimum fluorescence. 10 min later Cl^-^ was added back into the tissue buffer at 0.1, 1, 10, and 100 mM, allowing a Stern--Volmer relationship to be constructed (where F~0~/F denotes fluorescence in the absence of chloride divided by fluorescence in the presence of chloride), this relationship was used to construct a chloride ion standard curve from which neuron \[Cl^-^\]~i~ was calculated ([@B22]).

Following each experiment cells were fixed 4% (w/v) paraformaldehyde in PBS for 25 min at room temperature and then stored in PBS with 0.1% sodium azide (Sigma-Aldrich, Australia) until used for immunocytochemistry.

Dopamine ELISA
--------------

On days 20, 40, 60, and 80 of differentiation neurons were incubated with HEPES buffer (37^∘^C) containing nipecotic acid (6 μM) and AA (200 μM). The HEPES buffer was collected from each well 60 s after the application of KCl (30 mM), GABA (30 μM), Glut (30 μM), or vehicle. The order of addition of agents was randomized in each experiment. Following collection, samples were immediately frozen by placing vials on dry ice and then stored in liquid nitrogen until use. ELISA was performed using the dopamine ELISA kit (Genway Biotech., USA) according to the manufacturer's instructions. Optical density at 405 nm was measured immediately after the reaction was stopped using an EnVision 2.101 multilabel fluorescence plate reader (PerkinElmer, Australia) and dopamine concentrations of samples were interpolated using the standard curve generated.

Neurodegeneration Assay
-----------------------

Cells were differentiated for 80--90 days. eGFP was visualized using a Nikon A1R confocal microscope equipped with an environmental chamber to allow neuron survival. Z-plane stacks of *PITX3^eGFP/w^* neurons were taken every 2 h for up to 48 h. Ligands were added immediately following the first round of imaging (time = 0 h). Cell loss was defined by the fraction of eGFP fluorescence remaining in each field of view following the addition of MPP^+^ (50 μM), TNF (20 ng mL^-1^), PGE~2~ (300 nM), or vehicles. In some experiments the cell impermeant nuclear acid stain TO-PRO^®^-3 (1 nM; Invitrogen, Australia) was added to wells to establish when neuron membranes became permeable. *PITX3^eGFP/w^* neuron-containing fields of view were analyzed using Nikon Elements imaging software (Nikon, Japan). For analysis of neuron death, stacks of images were used to create maximum intensity projection images, which were then thresholded for eGFP. Given the presence of fluorescent beads developing in cultures images, especially after the addition of TNF, small fluorescent objects (with areas of less than \<50 μm^2^) were excluded from analysis prior. The total fluorescence area was then calculated before and after ligand and used to generate a ratio (post-ligand/pre-ligand). We also measured neurite length over time using the maximum intensity projection images, single cells with clear eGFP^+^ projections were identified from pre-ligand images and the neurites manually measured with a tracing tool. For this study we found the 2 h imaging to be invaluable since it enabled us to trace neurite outgrowth/retraction, even as the soma moved around the plate.

Statistical Analysis
--------------------

Results are presented as the arithmetic mean ± standard error of the mean (SEM) of at least three independent experiments. Statistical analyses were performed using GraphPad Prism v5.00 and later v6.00 (GraphPad Software, USA) and employed a Student's *t*-test (two-tailed), or one-way analysis of variance (ANOVA) with *post hoc* Bonferroni's or Dunnett's test as appropriate. Paired *t*-tests were used when treatments allowed for 'before and after' measurements of cell responses in live cell experiments. For experiments involving single cell measures of fluorescence intensity, *n* = 3, 60 cells indicates that changes were measured in 60 cells spread across three (temporally distinct) independent differentiations (∼20 cells per differentiation).

Results
=======

Generation of hPSC Reporter Line and Differentiation of PITX3^eGFP/w^ Neurons
-----------------------------------------------------------------------------

A ZFN pair together with a targeting vector was used to introduce an eGFP-puromycin cassette to pluripotent H9 hESCs at exon 1 of the endogenous PITX3 locus (**Figure [1A](#F1){ref-type="fig"}**). Targeting efficiency was 19% of total colonies picked and was confirmed with southern blot analysis (**Figure [1B](#F1){ref-type="fig"}**). A modified version of a recently described floor plate differentiation protocol ([@B23]; summarized in **Figure [2A](#F2){ref-type="fig"}**) was used to derive mDA neurons. Neural differentiation was evident by the polarization of cell bodies and increased size of initial colonies by day 4 (**Figure [2B](#F2){ref-type="fig"}**). By day 12 of differentiation wells were largely confluent, by day 20, small (10--20 μm) polar neuronal cell bodies could be seen (**Figure [2B](#F2){ref-type="fig"}**). From day 8 eGFP fluorescence positive cells were visible (**Figure [2C](#F2){ref-type="fig"}**). Wild type H9 cells differentiated under the same conditions did not show any eGFP fluorescence, nor did *PITX3^eGFP/w^* hPSCs differentiated without fate directing morphogens (i.e., SHH, FGF8, or CHIR; data not shown). Flow cytometry was used to quantify the emergence of eGFP during differentiation (**Figure [2D](#F2){ref-type="fig"}**). The number of eGFP^+^ cells present per well-increased from 0 at day 0 to 14.9 ± 0.3% by day 12, this remained stable until day 21 (**Figure [2E](#F2){ref-type="fig"}**; one-way ANOVA with *post hoc* Dunnett's test compared to day 0, *p* \< 0.05 and 0.001, *n* = 3).

![**Targeting eGFP to the endogenous PITX3 locus in hPSCs using zinc finger nucleases (ZFN).** **(A)** shows a schematic of the donor plasmid for targeting eGFP to the endogenous PITX3 locus; the strategy employed was based on that reported by [@B14]. PGK, human phosphoglycerol kinase promoter; PURO, puromycin resistance gene; loxP, loxP sites; pA, polyadenylation sequence. **(B)** Correctly targeted colonies (as determined by PCR) were generated with 19% efficiency, and subsequently confirmed by Southern blot analysis (modified from [@B12]).](fncel-09-00104-g001){#F1}

![***PITX3^**eGFP/w**^*cells appear during chemically defined monolayer differentiation**. **(A)** *PITX3^eGFP/w^* hPSCs were transferred in fragments to Geltrex coated plates in mTeSR media. After 3 days, or when wells became 50--60% confluent, differentiation was initiated in N2B27 media using containing LDN 193189 (LDN), SB 431542 (SB), recombinant mouse/human Sonic Hedgehog C25II (SHH), recombinant mouse fibroblast growth factor-8b (FGF8), purmorphamine (PUR), CHIR 99021 (CHIR), recombinant human glial cell line-derived neurotrophic factor (GDNF), recombinant human brain cell line-derived neurotrophic factor (BDNF), ascorbic acid (AA), DAPT, N^6^, 2′-*O*-dibutyryladenosine-3′, 5′-cyclic monophosphate (db-cAMP), and recombinant human TGF-β 3 (TGF-β). **(B)** Cell morphology transitioned from PSC fragments to immature neurons by day 20. **(C)** Cell bodies containing eGFP could be seen developing across cultures from day 8 to day 22 of differentiation. **(D)** The percentages of live eGFP^+^ cells in culture were observed using flow cytometry. **(E)** shows the percentage of live eGFP^+^ cells to day 21 (one-way ANOVA with *post hoc* Dunnett's test compared to day 0, ^∗^ indicates *p* \< 0.05 and ^∗∗∗^ indicates *p* \< 0.001, *n* = 3). **(F)** Upon extended differentiation, eGFP^+^ cells with neuronal morphology were seen in culture until at least day 80. Scale bars; 100 μm.](fncel-09-00104-g002){#F2}

Differentiated PITX3^eGFP/w^ Cells Display Transcript, Protein, and Functional Capabilities of Midbrain Dopaminergic Neurons
----------------------------------------------------------------------------------------------------------------------------

Maturation of cultures by re-plating onto laminin coated wells revealed bright eGFP^+^ cell bodies clearly evident from days 20 to 80 of differentiation (**Figure [2F](#F2){ref-type="fig"}**). These cells displayed neuronal morphology and possessed eGFP throughout their soma and associated processes (**Figure [2F](#F2){ref-type="fig"}**). Comparative gene expression analysis via quantitative PCR (qPCR) was performed on eGFP positive and negative fractions (plot shown in **Figure [3A](#F3){ref-type="fig"}**) collected via FACS at day 20, 40, 60, and 80 of differentiation. Between 4 and 8% live eGFP^+^ cells were collected on each sort (**Figure [3A](#F3){ref-type="fig"}**). eGFP^+^ sorted cells revealed an up-regulation of markers of the dopaminergic neuron phenotype; *DAT*, *AADC*, and *TH* as well as the floor plate markers *FOXA2*, *SHH*, *CORIN*, and the midbrain markers *LMX1A*, *WNT1*, *EN1*, *PITX3,* and *PAX6* at all time points compared to hPSCs (**Figure [3B](#F3){ref-type="fig"}**; one-way ANOVA with *post hoc* Dunnett's test, *p* \< 0.05, *n* = 3). eGFP^+^ cells also showed high levels of the neuronal marker *MAP2*, and the synaptic marker *SYP* (**Figure [3B](#F3){ref-type="fig"}**; one-way ANOVA, *p* \< 0.05, *n* = 3). The forebrain markers *NKX2.1* and *FOXG1*, as well as the hindbrain marker *HOXA2*, were predominantly expressed in the eGFP^-^ fraction (**Figure [3C](#F3){ref-type="fig"}**). *SYP* and *MAP2* enrichment were also found in the eGFP^-^ fraction (**Figure [3C](#F3){ref-type="fig"}**).

![**Transcriptional identity of*PITX3^**eGFP/w**^* cells is midbrain dopaminergic.** A second flow cytometry experiment was conducted to collect eGFP^+^ and eGFP^-^ cells for total RNA extraction and qPCR analysis on days 20, 40, 60, and 80. **(A)** Shows a typical FACS plot at day 20, and the strategy used to isolate eGFP^+^ and eGFP^-^ cells. This graph shows the percentage of live cells (from three independent experiments; ± SEM) sorted into the eGFP^+^ gate at each time point. **(B)** qPCR analysis of the mRNA from at least 10^6^ eGFP^+^ cells showed upregulation of neuronal and midbrain dopaminergic genes (compared to hPSCs; one-way ANOVA with *post hoc* Dunnett's test, *p* \< 0.001-0.05, *n* = 3 technical replicates of samples aggregated from three independently differentiating wells) at points between days 20 and 80 of differentiation. The *y*-axis shows the fold change in mRNA levels (Δ mRNA).**(C)** Shows a heat map of the ratio of mean transcript levels in the positive fraction : negative fraction. Fore, forebrain; mid, midbrain; floor, floorplate; hind, hindbrain.](fncel-09-00104-g003){#F3}

Next, we confirmed transcriptional profiling of eGFP^+^ cells using immunocytochemistry. Confocal microscopy at day 20 revealed abundant expression of the neuronal cytoskeletal protein β-III tubulin (TUJ1) as well as TH (**Figure [4A](#F4){ref-type="fig"}**). 96 ± 2% of TH^+^ cells were TUJ1^+^ (**Figures [4B](#F4){ref-type="fig"},[C](#F4){ref-type="fig"}**). eGFP^+^ cells also co-expressed TH (94 ± 2% of eGFP^+^ cells), FOXA2 (97 ± 1% of eGFP^+^ cells), LMX1A (90 ± 3% of eGFP^+^ cells), and the K^+^ inward-rectifying channel, GIRK2 (56 ± 4% of eGFP^+^ cells; (**Figures [4B](#F4){ref-type="fig"},[C](#F4){ref-type="fig"}**). GABA immunoreactivity was widespread from day 20 onward, but was rarely co-localized with eGFP (1 ± 1%; **Figures [4B](#F4){ref-type="fig"},[C](#F4){ref-type="fig"}**).

![***PITX3^eGFP/w^* cells express protein markers of midbrain dopaminergic neurons.** Immunocytochemical analysis of *PITX3^eGFP/w^* cultures was performed at day 20 in order to confirm the presence of an mDA neuronal phenotype. **(A)** Wells were replete with the neuronal marker β-III tubulin (TUJ1; green), which was almost always co-localized with the dopaminergic marker tyrosine hydroxylase (TH; red). The panels, from left to right, show low and high powered color-merges of TUJ1 and TH, in combination with the nuclear stain TO-PRO-3 (blue). **(B)** Immunocytochemical analysis of *PITX3^eGFP/w^* cultures was performed at day 20 in order to confirm the presence of an mDA neuronal phenotype. Populations of *PITX3^eGFP/w^* cells expressed mDA markers TH, FOXA2, LMX1A, and the A9 group marker GIRK2, but not the GABAergic marker GABA. **(C)** Shows the relative co-localization of protein markers at day 20. The columns represent the percentage of cells positive for both markers (data presented as mean ± SEM, *n* = 3 fields of view from independent wells). Scale bars; 100 μm.](fncel-09-00104-g004){#F4}

Functional Properties of PITX3^eGFP/w^ Neurons Develop During *In Vitro* Differentiation
----------------------------------------------------------------------------------------

To determine whether *PITX3^eGFP/w^* neurons were functional we performed live-cell fluorescent imaging to measure intracellular calcium (\[Ca^2+^\]~i~) and chloride ion (\[Cl^-^\]~i~) activity, as well as DA release during differentiation (**Figure [5A](#F5){ref-type="fig"}**). From day 20 around 20% of *PITX3^eGFP/w^* neurons (which were subsequently shown to be immunoreactive to TH) showed regular spontaneous elevations of \[Ca^2+^\]~i~ (**Figure [5B](#F5){ref-type="fig"}**) at a frequency of 3.3 ± 0.3 min^-1^ (**Figure [5C](#F5){ref-type="fig"}**). By day 80 the frequency of these events was 5.0 ± 0.1 min^-1^ (**Figure [5C](#F5){ref-type="fig"}**; change from days 20 to 80 was not significant, one-way ANOVA with *post hoc* Dunnett's test, *p*\> 0.05, *n* = 3). \[Ca^2+^\]~i~ in *PITX3^eGFP/w^* neurons was calculated at rest and after stimulation with KCl (30 mM; **Figure [5D](#F5){ref-type="fig"}**). Basal \[Ca^2+^\]~i~ increased during differentiation from 45 ± 13 nM at day 20 to 169 ± 25 nM at day 80 (**Figure [5E](#F5){ref-type="fig"}**; one-way ANOVA, *p* \< 0.001, *n* = 4, 60--80 cells). KCl (30 mM) increased maximal \[Ca^2+^\]~i~ from 357 ± 80 nM at day 20 to 931 ± 119 nM at day 80 (**Figure [5E](#F5){ref-type="fig"}**; one-way ANOVA, *p* \< 0.001, *n* = 4, 60--80 cells).

![**Functional characterization of*PITX3^**eGFP/w**^* neurons reveals development of maturity during terminal differentiation.** **(A)** Ca^2+^ and Cl^-^ imaging was employed to probe the function of *PITX3^eGFP/w^* neurons. These panels show, from left to right, eGFP in a field of view prior to imaging, the Ca^2+^ -sensitive probe Fluo-4 loaded into cells of the same field, and TH and eGFP after post-imaging immunocytochemistry. **(B)** Shows a representative trace from a Ca^2+^ imaging experiment. Spontaneous oscillations of \[Ca^2+^\]~i~, typical of *in vitro* mDA neurons are highlighted by arrows. The *y*-axis represents change in fluorescence: baseline fluorescence (ΔF/F). **(C)** The frequency of these oscillations did not change significantly by day 80 (one-way ANOVA with *post hoc* Dunnett's test, indicates *p* \> 0.05, *n* = 3 wells, 60--80 cells). **(D)** Intracellular calcium ion concentration (\[Ca^2+^\]~i~) in *PITX3^eGFP/w^* neurons was calculated at rest and after stimulation with KCl (30 mM). **(E)** Basal and KCl-induced elevations of \[Ca^2+^\]~i~ increased during differentiation (one-way ANOVA with *post hoc* Dunnett's test, ^∗∗∗^ indicates *p* \< 0.001, *n* = 3 experiments, 40--80 cells). **(F)** Similarly, GABA (30 mM) decreased \[Cl^-^\]~i~ at day 20 and 40 of differentiation, by day 80 GABA induced a significant increase in \[Cl\]~i~ (Student's paired *t*-test, ^∗∗∗^ indicates *p* \< 0.001, *n* = 4, 60--80 cells). **(G)** By day 80 most *PITX3^eGFP/w^* neurons respond to GABA with an elevation of \[Cl^-^\]~i~ (blue; *R*^2^ = 0.99), rather than the decrease seen at earlier days of differentiation (red; *R*^2^ = 0.99). **(H)** Shows the change in dopamine concentration in the supernatant of eGFP^+^ cultures following vehicle addition (i.e., basal level), GABA (30 mM), [l]{.smallcaps}-glutamate (30 mM) or KCl (30 mM) at different days of culture. Dopamine release in response to GABA (30 μM), but not [l]{.smallcaps}-glutamate or KCl significantly decreased from days 20 to 80 of differentiation (one-way ANOVA with *post hoc* Dunnett's test compared to day 20, ^∗∗^, ^∗∗∗^ indicates *p* \< 0.01 and 0.001, respectively, *n* = 3 wells).](fncel-09-00104-g005){#F5}

\[Cl^-^\]~i~ was calculated in *PITX3^eGFP/w^* neurons at rest and after stimulation with GABA (30 μM; **Figure [5F](#F5){ref-type="fig"}**). Basal \[Cl^-^\]~i~ decreased during differentiation from 5.8 ± 0.4 mM at day 20 to 2.1 ± 0.4 mM at day 80 (**Figure [5F](#F5){ref-type="fig"}**; one-way ANOVA, *p* \< 0.001, *n* = 4, 60--80 cells). At day 20, GABA significantly decreased basal \[Cl^-^\]~i~, but by day 80 GABA elevated basal \[Cl^-^\]~i~ (Student's paired *t*-test, *p* \< 0.001, *n* = 4, 60--80 cells). The proportion of *PITX3^eGFP/w^* neurons responding to GABA with an elevation of \[Cl^-^\]~i~ increased from 12% at day 20 to 82% at day 80 (**Figure [5G](#F5){ref-type="fig"}**).

Cultures containing *PITX3^eGFP/w^* neurons released DA both at rest, and following pharmacological stimulation using GABA (30 μM), Glut (30 μM), and KCl (30 mM; **Figure [5F](#F5){ref-type="fig"}**). Basal release of DA in culture increased during differentiation from 2.1 ± 0.3 ng mL^-1^ at day 20 to 3.22 ± 0.05 ng mL^-1^ at day 80 (**Figure [5F](#F5){ref-type="fig"}**; one-way ANOVA with *post hoc* Dunnett's test, *p* \< 0.01, *n* = 3). DA release following stimulation with GABA (30 μM) was 3.93 ± 0.86 ng mL^-1^ at day 20. By day 40, post-GABA DA release decreased and remained constant until day 80 (0.05 ± 0.16 ng mL^-1^; **Figure [5H](#F5){ref-type="fig"}**; one-way ANOVA with *post hoc* Dunnett's test, *p* \< 0.001, *n* = 3).

Next, the ability of *PITX3^eGFP/w^* neurons to respond to common neurotransmitters was investigated using Fluo-4 Ca^2+^ imaging. At days 20, 40, 60, and 80 *PITX3^eGFP/w^* cells responded to ATP (300 μM), GABA (30 μM), KCl (30 mM), NA (30 μM), Glut (30 μM), ACh (30 μM), and Ca^2+^ (10 mM) with elevations of \[Ca^2+^\]~i~ (percentages of eGFP^+^ cells responding to each neurotransmitter are shown in **Figure [6A](#F6){ref-type="fig"}**). **Figure [6B](#F6){ref-type="fig"}** shows the typical responses of cells responding to ATP from each time point, and also the mean (±SEM) increase in Ca^2+^-related fluorescence after ATP at each time point. *PITX3^eGFP/w^* neuron responsiveness to individual agents was close to 100% by day 80; the exception being NA, which elicited elevations of \[Ca^2+^\]~i~ in \<50% of cells (**Figure [6A](#F6){ref-type="fig"}**). We next looked at the ability of individual *PITX3^eGFP/w^* neurons to respond to multiple agonists in order to ascertain whether they became functionally restricted to specific pharmacological stimuli during maturation. At day 20 only 10 ± 9% of cells responded to all the neurotransmitters (ATP, ACh, NA, and Glut) with elevations of intracellular calcium. By day 80, this figure had risen to 48 ± 21% of all *PITX3^eGFP/w^* neurons (**Figure [6C](#F6){ref-type="fig"}**; one-way ANOVA with *post hoc* Dunnett's test, *p* \> 0.05, *n* = 3, 40--60 cells).

![**Neuropharmacology of *PITX3^eGFP/w^* neurons.** Ca^2+^ imaging of eGFP^+^ cells revealed functional neurons responding to neurotransmitters changes over time. **(A)** Shows the percentages of eGFP^+^ cells, at days 20 and 80 of differentiation, that respond to pharmacological stimuli with increases of \[Ca^2+^\]~i~ \>10 SD of baseline (mean ± SEM, *n* = 3). ATP, adenosine triphosphate; NA, noradrenaline; Glut, [l]{.smallcaps}-glutamate; ACh, acetylcholine; or V, vehicle. For example, at day 20 very few eGFP^+^ cells respond to all of ATP, NA, Ach and glutamate, this figure increases to ∼50% of neurons at day 80. **(B)** Shows typical *PITX3^eGFP/w^* neuron \[Ca^2+^\]~i~ responses to ATP on days 20--80. Mean fold changes in \[Ca^2+^\]~i~-related fluorescence in response to ATP (±SEM) are shown underneath. **(C)** Shows the effect of the cumulative addition of calcium channel inhibitors, nifedipine (10 μM), ω-conotoxin MVIIA (0.4 μM), and mibefradil (10 μM) on the KCl-induced change in \[Ca^2+^\]~i~ at day 80. KCl (30 mM) control responses in the presence of voltage operated calcium channel inhibitor vehicles did not significantly change throughout the experiment. All data was analyzed using a one way ANOVA with *post hoc* Dunnett's test compared to vehicle or day 20 data. (^∗^ and ^∗∗∗^ indicates *p* \< 0.05 and 0.001, *n* = 3).](fncel-09-00104-g006){#F6}

Lastly, in order to investigate the contribution of voltage operated Ca^2+^ channels to the KCl-induced elevations of \[Ca^2+^\]~i~ we examined the KCl-induced elevation of \[Ca^2+^\]~i~ in the absence and presence of three specific voltage operated Ca^2+^ channel inhibitors, added cumulatively, nifedipine (10 μM; L-type blocker), ω-conotoxin MVIIA \[0.4 μM; N (primarily)/P/Q type blocker\] and mibefradil (10 μM, T type blocker; **Figure [6C](#F6){ref-type="fig"}**). Nifedipine reduced the KCl-induced elevation of \[Ca^2+^\]~i~ by 27% (one-way ANOVA with *post hoc* Dunnett's test, *p* \< 0.05, *n* = 3, 60--80 cells). The subsequent addition of ω-conotoxin to nifedipine had no further effect on KCl-induced elevations of \[Ca^2+^\]~i~, but the addition of mibefradil to the combination of ω-conotoxin and nifedipine further reduced the KCl-induced elevation of \[Ca^2+^\]~i~ by 59% (**Figure [6C](#F6){ref-type="fig"}**; one-way ANOVA with *post hoc* Dunnett's test, *p* \< 0.001, *n* = 3, 60--80 cells).

PITX3^eGFP/w^ Neuron Responses to MPP^+^ and Neuroinflammatory Mediators
------------------------------------------------------------------------

To establish *PITX3^eGFP/w^* neurons as a tool for modeling neurodegeneration in PD we tested the effects of the neurotoxin MPP^+^, as well as two neuroinflammatory mediators: TNF, as well as prostaglandin E~2~ \[PGE~2~, which is elevated in response to MPP^+^ ([@B53])\] on mature *PITX3^eGFP/w^* neurons. **Figures [7A](#F7){ref-type="fig"},[B](#F7){ref-type="fig"}** show a typical field of view before (7A) and 24 h after TNF (20 ng mL^-1^, 7B). After 24-h exposure, MPP^+^ (5 μM) significantly (one-way ANOVA with *post hoc* Dunnett's test, *p* \< 0.05, *n* = 4 wells) reduced eGFP^+^ cell number by 49 ± 13%. TNF (20, but not 2 ng mL^-1^), PGE~2~ was without effect (**Figure [7C](#F7){ref-type="fig"}**, *n* = 10). Around 50% of cells were resistant to TNF, even when the incubation was continued for 72 h (not shown). When neurons did not clearly die we were able to measure GFP^+^ neurite lengths using Nikon software. Compared to vehicle control, TNF, but not PGE~2~ significantly (one-way ANOVA with *post hoc* Dunnett's test, *p* \< 0.05, *n* = 10 and 12) reduced neurite length over this time (**Figure [7D](#F7){ref-type="fig"}**). A lower concentration of TNF (2 ng mL^-1^ for 24 h) had no effect on neurite length (not shown).

![***PITX3^eGFP/w^* neuron death following MPP^+^ and TNF.** **(A)** Typical representative images of *PITX3^eGFP/w^* green neurons prior to **(A)** and after the addition of TNF (20 ng mL^-1^, 24 h, **B**). **(C)** Effects of MPP^+^ (5 μM) and tumor necrosis factor (20 ng mL^-1^), both 24 h on neurons survival (as defined by maintenance of somal fluorescence) (one way ANOVA with *post hoc* Dunnett's test compared to vehicle, ^∗^ indicates *p* \< 0.05, *n* = 3--12 differentiations). Prostaglandin E2 (300 nM) was without significant effect (not shown; **D**). Surviving neurons show neurite retraction following incubation with TNF (20 ng/ml), but not prostaglandin E2 (300 nM). Data presented as mean ± SEM (one way ANOVA with *post hoc* Dunnett's test compared to vehicle, ^∗^ indicates *p* \< 0.05, *n* = 6--12 differentiations). For death assays *n* = 6--12 fields of view. For fluorescent neurite tracing neurites length is expressed as a fraction of original length (i.e., pre-ligand) *n* = 4, with measurements taken from 16 neurons. Scale bar; 100 μm.](fncel-09-00104-g007){#F7}

Discussion
==========

Current mDA differentiation protocols yield heterogeneous neural cultures with mixed neurotransmitter and regional specifications. The first aim of this study was to generate a homologous hPSC reporter line to facilitate the identification, isolation, and characterization of mature mDA neurons. The second aim was to assess the responses of these neurons to pharmacological and toxicological stimuli. The endogenous *PITX3* promoter was chosen to drive eGFP since, in the adult CNS, PITX3 expression is restricted to DA neurons of the midbrain ([@B47], [@B48]), it also has a demonstrable role in the development, maturation, and survival of mDA neurons ([@B39]). PITX3-driven eGFP could be seen as early as day 8 of differentiation, from day 20 to termination, cultures contained 10--15% intensely fluorescent and clearly identifiable *PITX3^eGFP/w^* neurons.

To investigate the transcriptional changes in the *PITX3^eGFP/w^* neurons we used flow cytometry to collect eGFP^+^ cells at days 20, 40, 60, and 80. Although flow cytometry became more difficult over time as cultures developed extensive neuronal processes, we were consistently able to collect around 8% live cells for total RNA extraction. The transcriptional profile of *PITX3^eGFP/w^* cells was indicative of an mDA phenotype, with both the midbrain and floor plate markers; *PITX3*, *EN1*, *PAX5*, *FOXA2*, *SHH,* and *CORIN* highly upregulated compared to eGFP^-^ cells. In addition, the eGFP^+^ population showed a down-regulation of the anterior and posterior CNS markers, *NKX2*.1, *FOXG1*, and *HOXA2.* In contrast, *LMX1A* and *WNT1* were, unexpectedly, relatively down-regulated at various time points in the eGFP^+^ fraction compared to the eGFP^-^ fraction. Although *LMX1A* and *WNT1* encode critical mediators of early dopaminergic specification ([@B6]), they are also involved in other neural differentiation programs; for example, *LMX1A* also directs early forebrain fate while *WNT1* is involved in neural crest differentiation ([@B45]). Thus we think it is likely that *LMX1A* and *WNT1* may be expressed in the eGFP^-^ population as part of these other programs. As the cultures developed it became clear that the midbrain and floor plate markers *FOXA2*, *SHH*, *CORIN*, and *PAX5* expression decreased in eGFP^+^ cells, most likely as a consequence of neuronal maturation ([@B29]). This idea was supported by our data showing the presence of *DAT* transcript after day 60, possibly indicating the development of synaptic interactions. Consistent with this idea, the synaptic marker *SYP* was highly upregulated in the eGFP^+^ fraction, indicating the likely formation of functional synapses ([@B55]). Our profiling data are therefore consistent with the idea that PITX3 expressing neurons continue to develop during maturation and terminal differentiation.

We then used immunocytochemistry to confirm the transcriptional profile of developing *PITX3^eGFP/w^* neurons. Thus, TH, FOXA2 and LMX1A immunoreactivity was present in most *PITX3^eGFP/w^* neurons. GIRK2 was not present in all *PITX3^eGFP/w^* neurons, however, possibly indicating subpopulations of mDA neurons ([@B52]), or perhaps distinct stages in development. GABAergic immunoreactivity was observed during differentiation, however, it was rarely found in *PITX3^eGFP/w^* cells.

Functionally, the *PITX3^eGFP/w^* neurons displayed spontaneous elevations of \[Ca^2+^\]~i~ and were capable of spontaneous, GABA sensitive dopamine release. The variation in concentration of dopamine released during differentiation may be attributable to the state of maturity of the developing cultures: immature mDA neurons release dopamine to aid development through D~2~ autoreceptor-mediated Nurr1 activation ([@B20]), whereas mature neurons release dopamine predominantly through classic neurotransmitter release signaling ([@B49]). These properties of *PITX3^eGFP/w^* neurons are largely consistent with our current understanding of mDA neuron function *in vivo* ([@B40]; [@B16]). To confirm neuron maturation in culture we tested *PITX3^eGFP/w^* neurons with live cell ion imaging studies as previously described ([@B24]; [@B42]; [@B17]). As cultures matured we also saw both a decrease in \[Cl^-^\]~i~ as well as an increase in the proportion of *PITX3^eGFP/w^* neurons responding to GABA with increased \[Cl^-^\]~i~. These findings are consistent with a shift from immature to mature cultures ([@B43]; [@B41]). As \[Cl^-^\]~i~ decreased, basal \[Ca^2+^\]~i~ increased across cultures, lending support to the idea that following the expression of PITX3, neurons continue a relatively slow process of functional maturation.

These *PITX3^eGFP/w^* neurons responded to ATP, NA, ACh, and Glut with elevations of \[Ca^2+^\]~i~, indicating they were functionally responsive to multiple neurotransmitters. As cultures developed it became evident that more neurons responded to a greater number of ligands. Mouse PSC-derived TH^+^ neurons demonstrate variability in their responses to different neurotransmitters, at a time when cultures are mature ([@B42]; [@B54]), however, the present results indicate that extended differentiation of hPSC-derived mDA neurons results in a more homogenous pharmacological response to these neurotransmitters. Although we have not further characterized the receptors present, our functional data are broadly consistent with reports of the presence of ionotropic and metabotropic glutamate, GABA, acetylcholine and ATP receptor transcripts in human substantia nigra (see for example, E-GEOD-7621 and E-GEOD-20333; <http://www.ebi.ac.uk/>). These tissues samples also reveal multiple α- and β- adrenergic receptors, a finding consistent with our evidence that noradrenaline is capable of elevating intracellular calcium in *PITX3^eGFP/w^* neurons.

VOCCs are present on mDA neurons *in vivo* ([@B5]) and their tightly controlled activation contributes to the spontaneous activity observed in rodent dopaminergic neurons (see [@B28]). Our observation of spontaneous oscillations of intracellular calcium is likely to result from bursts of spontaneous electrical activity, clearly these events require extensive electrophysiological characterization before conclusions about their significance can be drawn. We also showed that a high concentration of nifedipine and as well as mibefradil, but not MVIIA reduced the elevation in \[Ca^2+^\]~i~ following KCl depolarization, indicating a role for L- and T- type VOCCs in hPSC-derived neuronal Ca^2+^ signaling. While we acknowledge that the single concentrations of inhibitor used in this study are not optimal we argue that the effects we see most likely indicate that these channels are present and functional in these cultures. Clearly, there is a need for further electrophysiological studies to pursue the identity and function of these channels. In addition, our studies are somewhat spatially limited in that they account only for Ca^2+^ channel present in the soma and they in no way allow prediction of which channel subunits may be present on the soma vs. dendrites; it is for example, dendritic calcium that regulates spontaneous activity, at least in dissociated rat neurons ([@B21]). It is evident from array data (see E-GEOD-7621 and E-GEOD-20333; <http://www.ebi.ac.uk/>) that multiple voltage gated channel subunits may be present in the human substantia nigra, but how these channels cooperate to regulate spontaneous bursts of activity is unclear.

Intracellular chloride decreases as neurons mature, a phenomenon that corresponds to a GABA related depolarization of immature neurons ([@B1]). Our cultured neurons showed a significant decrease in intracellular chloride over differentiation which correlates with a change in response to GABA where, early in differentiation GABA was a depolarizing agent, capable of reducing intracellular chloride, later in differentiation it increased intracellular chloride and inhibited dopamine release. Together these finding indicate a developing neuronal culture that largely consists of mature neurons from day 60 of differentiation. This last point is an important consideration as it demonstrates the importance of choosing an appropriate time for experimentation or implantation, although the fundamental significance of this work remains that *PITX3^eGFP/w^* neurons are most useful for neuropharmacological or neurophysiological studies (albeit from at least 60 days in culture).

In our next series of experiments we investigated the effects of the neurotoxin MPP^+^ and two neuroinflammatory mediators, TNF and PGE2 on *PITX3^eGFP/w^* neuron survival and neurite retraction. We chose these ligands since TNF is elevated in the striatal tissue of mice and rats following the injection of the neurotoxins, MPTP or 6-hydroxydopamine ([@B34]; [@B50]), while mice lacking TNF receptors are insensitive to the effects of MPTP ([@B50]). Furthermore the TNF inhibitor protein, dominant negative TNF, protects substantia nigral dopaminergic neurons against 6-hydroxydopamine-induced neuronal toxicity ([@B30]; [@B11]). Thus evidence linking TNF to the initiation and progression of PD is strong. In contrast to TNF, PGE~2~ has four cognate receptor subtypes, EPR1-4. [@B4] have found that EPR2 activation protects mDA neurons against low levels of oxidative stress while EPR1 activation renders mDA neurons vulnerable to such stress. A 24 h exposure to TNF, but not PGE~2~ significantly reduced the number of eGFP fluorescent cell bodies in culture and also induced the retraction of GFP^+^ neurites. Death of neurons occurred within 16 h of TNF addition, but neurite retraction was maximal at 24 h. Significantly, our data indicates that not all *PITX3^eGFP/w^* neurons were sensitive to the effects of TNF possibly indicating the presence of subtypes of *PITX3^eGFP/w^* neurons. Whether this difference equates to the difference between nigral and ventral tegmental dopaminergic neurons, or reflects the largely unknown identities of other cells in each well, is currently unknown.

As a final step we assessed *PITX3^eGFP/w^* neuron survival following the addition of the neurotoxin, MPP^+^. MPTP, the precursor of MPP^+^ is a well-described dopaminergic neurotoxin that is likely to produce excessive levels of reactive oxygen species and or an inhibition of mitochondrial activity to kill neurons ([@B46]). In this study a 24 h exposure to MPP^+^ significantly reduced eGFP fluorescence, a finding consistent with its reported activities*in vivo* and *in vitro*. Of significance is a report by [@B27] who suggest that the absence of one allele of Pitx3 in a mouse system increases sensitivity of TH^+^ neurons to MPTP. This work may indicate some potential for *PITX3* haploinsufficiency to increase the sensitivity of these PITX3^+^ neurons to neurotoxin-mediated death. However, we would argue that, in the absence of neurotoxic insult, these neurons are readily maintained in culture for at least 80 days. We interpret this as evidence that sufficient *PITX3* is present to maintain survival.

Conclusion
==========

We believe that progress in determining factor(s) that initiate and sustain idiopathic PD is hampered by the lack of a suitable *in vitro* model of human mDA neuron function. The hPSC *PITX3^eGFP/w^* reporter cell line described here has the potential to accelerate advancement in neurobiology, neuropharmacology, neurophysiology, and neurotoxicology as it permits the identification, sorting and tracking of live and dying mDA neurons in culture. These *PITX3^eGFP/w^* neurons show both receptor expression and activities that appear consistent with animal models and, more importantly, human array data. In particular we believe that these *PITX3^eGFP/w^* neurons will become a powerful tool in drug discovery biology as they readily permit investigation of the mechanisms underlying neuron function and degeneration.
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